Investor
Board of Directors
The board of directors holds overall responsibility for the company’s management and strategy. The board is structured to ensure independent operation while addressing the collective interests of all shareholders while meeting the company’s needs for expertise, capacity and diversity.
Morten Foros Krohnstad
Chairman of the board
Year of birth: 1968
Elected: 2020
Number of shares: 0
Field of expertise: Corporate law and corporate strategy
Morten Krohnstad is a partner in the law firm Schjødt and has extensive experience as a business lawyer and serves on several boards in Norwegian listed and un-listed companies. Krohnstad has a master’s in law from the University of Bergen, Norway.
Tone Kvåle
Member of the Board & Chair of the Audit Committee
Year of birth: 1969
Elected: 2024
Number of shares: 3.077
Field of expertise: Med-tech finance
Tone Kvåle is CFO of Herantis Pharma Plc. She has more than 25 years of experience from the biotech, medtech and life sciences industry. She has held CFO roles and senior management positions at several listed and unlisted companies, including Nordic Nanovector ASA and NorDiag ASA. She is member of the board and audit committee president of MedinCell, France, and has been board member and chair of the audit committee of Bonesupport AB, Sweden. Tone has a diploma in finance and administration from UiT, The Arctic University of Norway, Harstad. She has completed the prescribed course of study and the examination for Advanced Programme in Corporate Finance at The Norwegian School of Economics, NHH.
Hans Johan Hekland
Member of the Board & Member of the Audit Committee
Year of birth: 1958
Elected: 2021
Number of shares: 11.562
Field of expertise: Med-tech business development, strategy and finance
Hans Hekland is a managing partner in Sarsia Venture Management. He has extensive experience from board positions and involvement in the medical development companies and other listed and unlisted companies. He has broad expertise from fund management, strategy, business development and finance. Hekland holds a master of science in economics and business administration from the Norwegian School of Management, Bergen, Norway.
Trine Teigland
Member of the Board
Year of birth: 1990
Elected: 2020
Number of shares: 2.101.214
Field of expertise: International sales and marketing
Trine Teigland is the managing director of Teigland Eiendom AS. She has international experience from sales and marketing management of Osmotex AG in Switzerland, and one of the world’s leading providers of integrated shipping services in Singapore. Teigland holds an MBA from the University of St. Gallen, Switzerland, and a bachelor’s degree in international business.
Lutz Walter Heinemann
Member of the Board
Year of birth: 1954
Elected: 2020
Number of shares: 0
Field of expertise: R&D in diabetes technology
Lutz Heineman has broad academic background with a special focus on research and development in insulin pharmacology and diabetes technology. He has established and manages the Profil Institute for Metabolic Research in Neuss, Germany and is the Managing Editor of The Journal of Diabetes Science and Technology.
Group management
The Group management team is responsible for overseeing the company’s daily operations, ensuring alignment with its strategic goals.
Joachim Holter
Chief Executive Officer
Year of birth: 1976
In position since: 2020
Number of shares: 124.951
Joacim Holter has close to 20 years of management experience, including six years’ experience leading international R&D and product development based in Switzerland. He has broad experience from board positions including as chairman and later member of the Lifecare Board of Directors from 2011 to 2020. He has also managed his own lawyer practice for 16 years. Holter holds a master’s in law from the University of Bergen, Norway.
Andreas Pfützner
Chief Scientific Officer
Year of birth: 1960
In position since: 2017
Number of shares: 138.485
Andreas Pfützner has over 30 years of pharmaceutical and device development experience within diabetes technology. In addition to being the CSO of Lifecare, he is the Managing Director of Pfützner Science & Health Institute GmbH, a diabetes center & practice. He is also professor for internal medicine and laboratory medicine at DTMD University in Luxembourg. Pfützner holds a doctor degree in medicine from the University Hospital in Frankfurt, Germany and a PhD in medicine and chemistry from the University of Mainz, Germany.
Renete Kaarvik
Chief Financial Officer
Year of birth: 1974
In position since: 2024
Number of shares: 0
Renete Kaarvik has 25 years of experience from various positions within corporate finance, auditing and advisory services. She has broad experience from group finance positions in companies listed on Oslo Børs, including Grieg Seafood ASA and Marine Harvest ASA (now Mowi ASA). Former positions were within transactions services in EY and auditing in PwC, amongst others. Kaarvik holds a master’s degree in applied finance from Macquarie University in Sydney, Australia and a master of science in business.
Nomination committee
Lifecare’s nomination committee has three members elected at the annual general meeting. The nomination committee’s work is carried out in accordance with instructions adopted by the general meeting. The duties of the nomination committee are to present recommendations to the general meeting on candidates for election to the board of directors and for the nomination committee.
Proposals for new candidates to the board of directors or the nomination committee can be submitted to the nomination committee leader Christian Hysing-Dahl: chd@hantri.no
Scientific advisory board
Lifecare has a scientific advisory board, which consists of highly reputable experts within diabetes technology, clinical medicine, endocrinology, physics and nanotechnology. The chair of the scientific advisory board is Prof. David Klonoff, an endocrinologist specializing in the development and use of diabetes technology.
General meetings
Shareholders are the owners of the company, and the general meeting serves as the company’s supreme governing body. The annual general meeting is held by 30 June each year, while extraordinary meetings are called when necessary to address specific matters. Notices and supporting documents will be published on the company’s website at least 21 days before the meetings.
Event
Extraordinary General Meeting
Sep 17, 2024
For the planned uplisting from Euronext Growth Oslo to Oslo Børs, a share consolidation is required to meet the NOK 10 per share listing requirement. Additionally, to address shareholders with fractional shares post-consolidation, the Board proposes General Meeting’s approval to acquire treasury shares.
Extraordinary General Meeting
May 16, 2024
The Board proposes that the extraordinary general meeting resolves to increase the Company’s share capital by a partially underwritten rights issue. In order to create an incentive for subscriptions in the Rights Issue, the Board proposes issuance of warrants.
Annual General Meeting
Apr 30, 2024
Annual General Meeting
Apr 18, 2023
Annual General Meeting
May 6, 2022
Documents & policies
The corporate governance framework ensures accountability, fairness, and transparency in our relationship with stakeholders, including shareholders, management, employees and the broader community.
